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Abstract:
Histamine H3 receptors (H3R) are
widely expressed in the brain where they
participate in sleep-wake cycle and
cognition among other functions. Despite
their high expression in some regions of the
basal ganglia, their functional role in this
forebrain neural network remains unclear.
The present findings provide in situ
hybridization and immunohistochemical
evidence for H3R expression in several
neuronal populations of the rat basal
ganglia but not in astrocytes (glial fibrillary
acidic protein immunoreactive cells). We
demonstrate the presence of H3R mRNA
and protein in dopaminergic neurons
(tyrosine hydroxylase positive) of the
ventral tegmental area and substantia nigra.
In the dorsal and ventral (nucleus
accumbens) striatal complex we show H3R
immunoreactivity in cholinergic (choline
acetyltransferase immunoreactive) and
GABAergic neurons (substance P,
proenkephalin or dopamine D1 receptor
positive) as well as in corticostriatal
terminals (VGLUT1-immunoreactive).
Double-labelling experiments in the medial
prefrontal cortex show that H3R is
expressed in D1R-positive interneurons and
VGLUT1-positive corticostriatal output
neurons. Our functional experiments
confirm that H3R ligands modulate
dopamine synthesis and the probability of
glutamate release in the striatum from
cortico-striatal afferents. The presence of
H3R in such different neuronal populations
and its involvement in the control of striatal
dopaminergic and glutamatergic
transmission ascribes a complex role to H3R
in the function of the basal ganglia neural
network.
Abbreviations
 Acb: nucleus Accumbens; D1R: dopamine
receptor 1; H3R: histamine receptor 3; PE:
proenkephalin; SNc: substance nigra pars
compacta; SNr: substance nigra pars
reticulata; SP: substance P; SSC: sodium
saline citrate; TBS: 50mM tris buffer saline
pH 7.6; TSA: tyramide signal amplification;
VGLUT1: vesicular glutamate transporter 1 ;
VTA: ventral tegmental area
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Introduction
Histamine is involved in a variety of
brain functions such as the sleep-wake
cycle, attention, learning, memory and the
control of food intake and locomotion [1,2]
through its interaction with four identified
G-protein coupled receptors. Three of them
(H1 to H3) are widely distributed in the
central nervous system while the H4
receptor is expressed mostly in bone
marrow and leukocytes, displaying very low
levels in brain [3,4].
The histamine H3 receptor (H3R) was
initially described as an autoreceptor
controlling histamine release and synthesis
in histaminergic terminals of the central
nervous system [5,6]. Later, its
heteroreceptor role was demonstrated as it
also modulates the release of other
neurotransmitters including serotonin [7],
norepinephrine [8], dopamine [9],
glutamate [10] and GABA [11] in brain
samples. Many human and rat H3R mRNA
isoforms are generated by differential
splicing [12]. In the rat, four isoforms are
functionally active: H3(445), H3(413), H3(410),
H3(397). H3(413) has been suggested to be the
autoreceptor of histaminergic neurons [13].
The H3R isoforms have a heterogenous
expression level in cerebral structures [14]
being highly expressed in cortex, thalamus
and caudate-putamen [15]. This regional
localisation matches the relative
distribution of histaminergic projections
arising from the tuberomammillary nucleus.
In addition, radioligand binding studies in
rodents show high H3R levels in olfactory
nucleus, cortex, substantia nigra pars
reticulata (SNr), amygdala, thalamus and
hypothalamus, specially in
tuberomammillary nucleus, with the highest
density in striatum and nucleus accumbens
[16].
The rat striatum is the main input
structure of the basal ganglia involved in
sensory-motor behavioural coordination. It
can be divided in dorsal and ventral regions:
Dorsal striatum (caudate-putamen) has
been implicated in the initiation and
development of a voluntary motor
behaviour, while the ventral striatum
(nucleus accumbens, Acb) plays a central
role in motivated and goal directed
behaviours because it integrates
information from motor and limbic systems
[17]. Dorsal and ventral striatum differ in
afferences and efferences, but both present
the same neuronal phenotypes. Thus 95%
of striatal neurons are GABAergic spiny
projection neurons, which can be divided in
two populations: striato-nigral pathway
neurons which show dynorphin, substance
P (SP) and D1-like dopamine receptors and
striato-pallidal pathway neurons that
coexpress enkephalin and the D2-like
dopamine receptor [18,19]. Nevertheless,
discrimination between these two
populations is not absolutely clear because
all of these neurons can express low levels
of characteristic receptors of the other
neuronal type [20, see also 21]. The
remaining 5% of striatal neurons is
composed by interneurons of two subtypes:
cholinergic and GABAergic [22].
Striatal neurons are a major target
of mesencephalic dopaminergic neurons,
which are implicated in complex
neurological and psychiatric disorders such
as Parkinson, Huntington, schizophrenia
and addiction. The role of H3R in normal
striatal functions such as locomotion
control is not clearly elucidated [23,24], and
even less in pathological conditions.
However, the therapeutic potential of H3R
antagonists is being studied in sleep-wake
disorders, dementia, attention-deficit
hyperactivity disorders, and schizophrenia
[25,26]. Conversely, stimulation of H3R
decreases L-dopa-induced chorea and
turning behaviour in animal models of
Parkinson’s disease [27,28]. In the present
work functional histamine H3R expression in
basal ganglia neuronal populations is
studied to evaluate the possibility that H3
receptors constitute new targets for
treatments of these disorders.
Experimental procedures
Tissue preparation for histochemistry
 Experiments performed in the
present study conformed to the Ethics
Committee for Human and Animal Research
(Universidad Autónoma de Barcelona) in
accordance with the European
Communities Council Directive of 24
November 1986 (86/609/EEC). Brains were
obtained from male OFA-Sprague-Dawley
rats weighing 200-250 g (Animal Service,
Universidad Autónoma de Barcelona,
Barcelona, Spain). Animals were sacrificed
by decapitation, their brain was removed
rapidly, immediately frozen (-40ºC) by
immersion in isopenthane and stored at -
20ºC. Brain sections (10µm) were prepared
on a cryostat and thaw-mounted onto
Superfrost slides. Slices were fixed for 40
min at 4ºC in freshly prepared 4%
formaldehyde made up in 0.1M phosphate
buffer pH 7.4, rinsed three times (5 min
each) in 0.1M phosphate buffered saline,
pH 7.4, dehydrated through graded ethanol
and dried. All the sections were stored at -
20ºC until use.
Fluorescent in situ hybridization
histochemistry
Brain sections were incubated at
37ºC for 10 min with proteinase K (5µg/ml),
acetylated for 10 min (in 0.1M
triethanolamine, pH 8 and 0.25% acetic
anhydride) at room temperature and
dehydrated in graded ethanol up to 100%.
Hybridization was performed overnight at
55ºC in the presence of 10-20 ng of
biotin/digoxigenine labelled antisense or
sense probes in hybridization buffer (50%
formamide, 10% dextran sulfate, standard
saline citrate 2x (SSC), 1% Denhart’s
solution, 50mM Tris-HCl buffer, 0.1% NaPPi,
0.2mg/ml tRNA, 1mM EDTA). Subsequently,
sections were rinsed with: 50% formamide
in SSC2x (30 min at 55ºC), SSC2x (5 min at
55ºC, 2 times 10 min at room temperature)
and incubated for 40 min at 37ºC with
ribonuclease. Then, sections were washed
in graded SSC (4x and 2x, 15min each, 0.1x
30 min at 60ºC and 0.1x 10 min room
temperature), Tris buffered saline 50mM
pH 7.6 (TBS) –Tween 20 0.05% three times
(5 min each) and blocked with 1% blocking
reagent (Roche Applied Science) in TBS for 1
h at 37ºC. They were then incubated for 2 h
at room temperature in a humid chamber
with the primary antibodies sheep anti-
digoxigenine–peroxidase (Roche Applied
Science, 1/100) and mouse anti-Biotin
(Jackson Immunoresearch, 1/200) diluted in
buffer (TBS, 0.1% acetylated bovine serum
albumin, 1% goat serum, 0.1% Tween 20).
After three rinses with TBS-Tween 20 0.05%
(5 min each) sections were incubated with
the green secondary antibody anti-mouse-
Alexa488 (Invitrogen, 1/200) diluted in TBS-
Tween 20 0.1% for 2 h at room
temperature. Two more washes followed by
one in TBS without Tween 20 (5 min) were
performed before the incubation with the
red fluorophore, which is conjugated to
tyramide signal amplification (TSA)-Cy3
activated by peroxidase (Perkin Elmer,
1/500). Finally, sections were washed and
mounted with Mowiol.
The H3R probe corresponded to
nucleotides 636-1243 of the rat H3R
sequence. It was previously shown to
hybridize to the various H3R mRNA isoforms
expressed in the brain or peripheral tissues
[14,16]. The tyrosine hydroxylase probe
used to detect dopaminergic neurons was
complementary to rat tyrosine hydroxylase
mRNA sequence from nucleotide 25 till the
end. cDNAs for proenkephalin (PE) and SP
were obtained by polymerase chain
reaction and corresponded to nucleotides
335-641 (GenBank accession n° AH002996)
and nucleotides 80 - 227 (AH002233),
respectively. They were subcloned into
pGEM-4Z (Promega) plasmids. Antisense
and sense cRNA riboprobes were prepared
by in vitro transcription. The sense probe
was used as a control for the specificity of
the signal obtained with the antisense
probe.
Fluorescent immunohistochemistry
Brain sections were thawed at 4ºC,
washed in TBS for 5 min, then in sodium
borohydrate 1% (diluted in disodium
hydrogenphosphate 0.1M pH 7.8) for 20
min and rinsed in phosphate buffer saline
50mM pH 7.4 and TBS (3 min each).
Blocking was made with 7% donkey serum
in TBS for 1 h at 37ºC. Primary antibodies
(listed in Table 1) were diluted in buffer
(TBS, acetylated bovine serum albumin 1%,
Tween 20 0.1%, 7% donkey serum) and
incubated overnight at 4ºC. Histamine H3
receptor expression in dopaminergic and
cholinergic neurons was detected using the
Abcam antibody while the Alpha Diagnostic
H3R31A antibody was employed for the
other experiments as they showed similar
immunostaining (Fig. 3). The H3R signal
specificity was tested by comparing three
different commercial antibodies and by
blocking Alpha Diagnostic anti-H3 (H3Ral)
signal with its blocking peptide. After three
washes in TBS-Tween 20 0.05%, sections
were incubated with the secondary
antibodies diluted in the same buffer as the
primary. Specificity of the secondary
antibodies employed was tested by control
experiments without primary antibody.
Three more washes with TBS-Tween 20
0.05% and TBS were done prior the
incubation of 5 min with Hoechst33258
(diluted 1/1000 in TBS) for nuclei
visualization. Final washes in TBS were
made before the mounting with Mowiol.
Sections were analyzed with a Nikon
Eclipse 90i microscope equipped with
conventional fluorescence: (1) DAPI filters
(340-380nm excitation, 435-485nm
emission), (2) FITC filters (465-495nm
excitation, 515-555nm emission) and (3)
G2-A filters (510-560nm excitation, 590
emission). Fluorescent images were
captured with a high resolution (1280x1024
pixels) Nikon digital DXM1200F camera
interfaced with the ACT-1 Nikon software.
Image signal levels were adjusted using
Adobe Photoshop software for a better
visualization. Original images have been
kept. Confocal images are a Z-stack of 5
photos (1µm/slice) made with an Olympus
FluoView FV1000 (Olympus) microscope
equipped with a UPLSAPO 60x NA: 1.35
objective. The following lasers were used: a
488nm laser (488nm excitation, 520nm
emission) and a 559nm laser (559nm
excitation, 618nm emission). Since the
intensity of immunolabelling for the
antibodies used could be due to many
variables that cannot be individually
quantified, this study does not attempt to
quantify the relative amounts of labelled
antigens. Colocalization of both antigens
were measured with the FV10-ASW 1.7
software (Olympus) and are shown as
average overlap ± standard deviation of
seven different regions of interest for each
image. When the overlap value is above 0.5
we consider both antigens colocalized.
Electrophysiology
The protocol used was adapted from
[29] and was as follows: Brains from male
Sprague-Dawley rats of 5 - 9 weeks of age
were rapidly extracted and placed in ice-
cold Krebs buffer containing 124 mM NaCl,
3.5 mM KCl, 25 mM NaHCO3, 1.25 mM
NaH2PO4, 1 mM CaCl2, 2 mM MgSO4, 10
mM glucose, 10 mM Hepes (pH 7.4) and
oxygen saturated (95% O2/5% CO2). Sagital
corticostriatal slices (350 µm) were
prepared from tissue blocks of the brain
with a Vibratome (Leica, VT1000S) and
maintained at least 2 h at room
temperature in the Krebs buffer, containing
2 mM CaCl2. This medium was used for
further recordings. A single slice was
transferred to a recording chamber of an
upright microscope (DMLFS, Leica). The
slice was positioned under a nylon mesh
and continuously superfused with oxygen
saturated Krebs solution (flow rate 2
ml/min) maintained at 30-32ºC.
Extracellular recordings were made using a
glass micropipette (flame polished
borosilicate capillary, inside diameter 0.58
mm, outside diameter 1 mm, Warner
instruments; resistance 4-7 MΩ) with a wire
(silver, 250 µm, A-M Systems) filled with
perfusion medium and placed in the dorsal
striatum. Afferent fibers were stimulated by
delivering monophasic voltage pulses at a
frequency of 0.05 Hz to a bipolar electrode
(nickel chrome wire, bare diameter 50 µm,
A-M Systems) connected to a multi-channel
external stimulator (STG4, Multi channels
systems) controlled by the software MC
Stim (Multi channels systems). The
stimulating electrode was placed in the
corpus callosum, or in the striatum close to
the border of the corpus callosum.
Stimulation intensity ranged from 100-800
µA and 80-600 ms. The recording electrode
was connected to a patch-clamp amplifier
(Axopatch 200 B, Axon Instruments). Signals
were digitized (Digidata 1200 Interface,
Axon Instruments) and filtered at 2 kHz.
Paired-pulse ratio was obtained by applying
two stimuli with a 50 ms interval and
calculated by dividing the second field
potential amplitude by the amplitude of the
first one (P2/P1). Data were collected by
Win LTP (kind gift by Dr. W. Anderson,
University of Bristol, UK). The amplitude of
the field potential was used as a measure of
synaptic transmission. After obtaining a
stable baseline of at least 15 min,
thioperamide was diluted in the Krebs
solution and bath-applied. Field potential
amplitudes were normalized to baseline
amplitude. Each data point used for
statistics was the mean of 8 consecutive
field potentials. Results were pooled in
Sigmaplot (Sigmaplot version 9) and
represented as means (± SEM) of n= 5
animals.
Dopamine synthesis
Fresh rat brains were chilled
immediately in modified Krebs-Ringer-
bicarbonate medium with the following
composition: 120 mM NaCl, 0.8 mM KCl, 2.6
mM CaCl2, 0.67 mM MgSO4, 1.2 mM
KH2PO4, 27.5 mM NaHCO3, and 10 mM
glucose, pH 7.4, saturated with 95% O2/5%
CO2. In a 4ºC room, striata (including
nucleus accumbens) were dissected and
sliced using a McIlwain tissue chopper to
obtain miniprisms of 0.3-0.3 mm/side.
Miniprisms were suspended in the same
medium and washed by centrifugation and
resuspension to remove cell debris.
Miniprisims were distributed into 2 ml
polypropylene tubes and preincubated for
15 min at 37ºC in an Eppendorf
Thermomixer under 95% O2/5% CO2
atmosphere. Imetit (H3R agonist) or vehicle
was added and preincubation continued for
10 min. Then ring-labeled [3,5-3H]-L-
tyrosine (40–60 Ci/mmol) was added to all
samples (final concentration of 0.12 μM)
and incubation continued for 10 min to
synthesize [3H]-dopamine. Synthesis was
stopped by the addition of a deproteinizing
solution containing trichloroacetic acid and
100nmol internal standard dopamine per
tube. Blank tubes contained deproteinizing
solution prior to [3H]-tyrosine and were
kept ice-cold throughout. All samples were
homogenized in a Dynatech/Sonic
Dismembrator (Dynatech Labs). An aliquot
was taken for protein quantification by the
Lowry method to take into account the
variability of tissue amounts in each tube.
Tissue homogenates were then centrifuged
(12,000 g, 10 min, 4ºC), and supernatants
were recovered for [3H]-dopamine
purification by HPLC-UV.
The chromatography system
consisted of a reverse-phase C18 column
(Tracer Extrasil ODS2, 5-mm particle size, 25
x 0.46 cm; Teknokroma) and an ion-pair
mobile phase, made up of 100 mM sodium
phosphate buffer, 1 mM EDTA, 0,75 mM
octanesulfonic acid plus 12% (v/v) methanol
(pH 5). Flow rate was 1 ml/min. Internal
standards were detected by UV 285 nm.
Radiolabelled and endogenous tyrosine and
dopamine were undetectable by UV
absorbance. Recovery of the internal
standard was quantified in each sample
(internal/external standard peak area).
Dopamine fractions were collected in
scintillation vials, mixed with Optiphase
HiSafe III cocktail (Wallac), and [3H]-
dopamine was quantified in a liquid
scintillation counter. Dpm obtained were
corrected by dopamine internal standard
recovery, dpm in blank samples, and
protein content in each incubated tube.
Results were expressed as percentage
versus control samples in the same
experiment.
Results
H3R mRNA and protein expression in
mesencephalic dopaminergic neurons.
In a previous study of H3R mRNA
distribution in several brain regions [16], no
expression was apparent in the ventral
tegmental area (VTA). In contrast in the
present work we do describe H3R mRNA
expression in the VTA using the same H3R
cRNA probe for in situ hybridization as [16].
TSA amplification permitted to visualize H3R
expression, particularly in dopaminergic
neurons of the VTA identified by tyrosine
hydroxylase mRNA (double in situ
hybridization) and protein (double
immunohistochemistry; Fig. 1A). In
agreement with Pillot et al [16] we confirm
the presence of H3R mRNA and protein in
substantia nigra pars compacta (SNc, Fig.
1B), particularly in dopaminergic neurons.
Additional neuronal populations of SNr also
showed H3R labeling (data not shown). The
Pillot et al (2002) study also showed a low
but significant binding of the H3R ligand
[125I]-iodoproxyfan in the VTA as compared
to the SNc. Thus, our results would agree
with them after improvement of signal
detection with TSA. Nevertheless, we
controlled the specificity of the H3 cRNA
antisense probe used for in situ
hybridization with the sense probe. In both
our study and [16] a very low non-specific
signal was detected in the VTA with the
sense probe (Fig. S1), but it was almost
undetectable when compared with the
specific signal of the antisense probe in the
same conditions. We also controlled the
specificity of the H3R antibodies used by
comparing three different commercial
antibodies (listed in Table 1) obtaining the
same signal pattern. These antibodies
where previously used in several studies
[30,31]. Moreover, the signal specificity of
the Alpha Diagnostic anti-H3R (anti-H3Ral)
antibody was completely abolished by
preincubation with its blocking peptide (Fig.
S2)
H3 receptors inhibit dopamine synthesis
Striatal dopamine synthesis takes
place in dopaminergic terminals arising
from VTA and SNc. To search for H3R
function in dopaminergic neurons we chose
to determine dopamine synthesis in
miniprism preparations of freshly dissected
striatum. In the presence of different
concentrations of the H3R agonist imetit,
[3H]-dopamine synthesis from [3H]-tyrosine
was decreased by 65 % vs. controls (p<0.01
oneway ANOVA; Fig. 2). This result was
representative of three independent
experiments, and it confirms a previous
report with a different H3R agonist [9]. This
suggests that H3R are functional inhibitory
heteroreceptors in dopaminergic neurons.
H3R protein and mRNA expression in
striatal neurons
Next we studied the presence of H3R
mRNA (Fig. 3) and protein (Fig. 4) in striatal
GABAergic projection neurons.
Approximately half of H3R mRNA-positive
neurons corresponded to each population
of SP or PE-expressing GABAergic projection
neurons (Fig. 3). Almost all SP mRNA
positive neurons expressed H3R mRNA (111
double-labelled of 126 SP positive neurons
in accumbens and 115 of 133 in striatum).
Similarly, almost all PE mRNA positive
neurons expressed H3R mRNA (131 double-
labelled of 140 PE positive neurons in
accumbens and 141 of 160 in striatum).
We also studied the colocalization of
H3R protein and dopamine D1 receptor
immunoreactivities. Dopamine D1 receptor
immunoreactivity was more intense in
neuronal somas, although it showed a
pattern of expression suggesting terminal
labelling. Using confocal imaging, we found
H3R-D1R colocalization (Fig. 4) in the H3R
positive neurons of the medial prefrontal
cortex, dorsal striatum and nucleus
accumbens (overlap values 0.71±0.01,
0.67±0.05 and 0.71±0.03 respectively) and
also in H3R positive terminals of these areas
(overlap values 0.70±0.02, 0.70±0.03 and
0.74±0.04 respectively).
Although H3R activation modulates
acetylcholine release [32,33,34], the
presence of H3R on cholinergic neuron
terminals had not yet been clearly
established. We found H3R
immunoreactivity in virtually all accumbal
(10 double-positive of 10 cholinergic
neurons)  and striatal (17 double-positive of
17 cholinergic neurons) cholinergic
interneurons, as shown in Fig. 5. Cholinergic
interneurons were identified by choline
acetyltransferase (ChAT) immunoreactivity
and by their big size.
H3R protein expression in glutamatergic
endings. Effects on glutamate release.
The striatum receives a modulatory
histaminergic input arising from the
tuberomammillary nucleus of the
hypothalamus [35] and three major
synaptic inputs: the dopaminergic
nigrostriatal pathway and the glutamatergic
corticostriatal and thalamostriatal pathways
[36].  These two glutamatergic inputs to
striatal neurons can be easily distinguished
on the basis of the vesicular transporter
used for glutamate storage. Thalamic
neurons express the vesicular glutamate
transporter 2 while cortical neurons
innervating the striatum express the
vesicular glutamate transporter 1 (VGLUT1)
[37]. As Fig. 6 shows, we found that H3R are
highly expressed in glutamatergic
corticostriatal nerve endings (VGLUT1
immunoreactive) in striatum and nucleus
accumbens (overlap values 0.75±0.08 and
0.72±0.04 respectively) as well as in
glutamatergic terminals in the medial
prefrontal cortex (overlap value 0.68±0.08).
At the same time, we found H3R-VGLUT1
colocalization in the external border of
some H3R positive neurons in medial
prefrontal cortex, striatum and nucleus
accumbens (overlap values 0.54±0.03,
0.60±0.03 and 0.62±0.05 respectively),
while central area of the neurons only
showed H3R immunoreactivity.
To determine if H3 receptors found
on glutamatergic corticostriatal endings
were functional, we recorded field
potentials elicited by cortico-striatal
stimulation. The application of H3R
antagonist/inverse agonist thioperamide
(100 nM) to fresh striatal brain slices
induced an increase of field potential
amplitude accompanied by a decrease of
the paired-pulse ratio (Fig. 7). This effect
persisted during thioperamide application
(30 min) and after washout (p<0.05
repeated-measures ANOVA), resulting in an
enduring potentiation of field potential
amplitude. A change in paired-pulse ratio is
generally interpreted as a changed
probability of neurotransmitter release
reflecting a presynaptic action of the
studied molecule. Thus the effects of 100
nM thioperamide clearly suggest a
potentiation of corticostriatal glutamate
release mediated by blockade of inhibitory
H3R present in corticostriatal nerve endings.
H3R protein is not expressed in GFAP-
immunoreactive astrocytes.
Astrocytes detected with an
antibody against its specific marker, the glial
fibrillary acidic protein (GFAP), are present
in diverse brain areas including the
neostriatum, the substantia nigra and the
cortex [38]. We analyzed the possible
presence of H3R in astrocytes and found no
colocalization between H3R and GFAP
proteins in medial prefrontal cortex,
striatum or nucleus accumbens (Fig. 8).
Overlap values obtained in these three
brain regions were 0.29±0.03, 0.26±0.07
and 0.27±0.07 respectively, always below
the preestablished threshold to detect
colocalization.
Discussion
In the present work we describe the
presence of histamine H3 receptor
expression in several neuronal types of rat
basal ganglia: (1) nigrostriatal and
mesolimbic dopaminergic neurons; (2)
striatonigral and striatopallidal GABAergic
neurons; (3) striatal cholinergic
interneurons and (4) corticostriatal
glutamatergic terminals. In addition, we
show that H3 receptors appear to be
functional in dopaminergic and
glutamatergic cells. Thus H3R are expressed
in diverse cellular types and could mediate
most histamine actions in these structures
[39].
We describe for the first time H3R
mRNA presence in the VTA, which was not
found in the study of brain H3R distribution
by Pillot et al. [16]. The reason for this
discrepancy could be due to the sensitivity
of methodological procedures. In the Pillot
et al. work a 33P radioactive probe was used
for a one-week exposition time, a relatively
short and probably insufficient period for
low levels of mRNA expression. In our case
we used the same cRNA probe as Pillot et
al. but we detected it with the potent TSA
amplification system. This improvement
revealed H3R mRNA expression in the VTA,
specifically in dopaminergic cells. Pillot et al.
also studied the brain distribution of H3R
protein by binding with the H3R antagonist125I-iodoproxyfan. They found minimum
binding in the VTA, much lower than in the
dorsal striatum, Acb, cortex and substantia
nigra (noteworthy weaker in SNc than in
SNr, suggesting predominant H3R
expression in striatonigral neurons as
compared to nigrostriatal neurons). Using
fluorescent immunohistochemistry we have
confirmed H3R receptor presence in those
areas (cortex, dorsal striatum, Acb, SNc and
also VTA), but a comparison between
regions was not attempted due to the
difficulties of fluorescence quantification.
Although H3R expression can be lower in
the VTA and SNc than in other regions, we
show it is clearly present in dopaminergic
neurons characterized both by tyrosine
hydroxylase immunoreactivity and mRNA
expression. Furthermore, H3R stimulation
decreased dopamine synthesis in striatal
tissue (Fig. 2 and [9]), as expected according
to the typically inhibitory role of H3R in
other cells [5,6]. Although dopamine
release could also be modulated by H3R,
this effect was more clearly described in the
prefrontal cortex than in the striatum
[40,41]. In the Acb shell H3R ligands
modulate methamphetamine-stimulated
dopamine release, but fail to modulate non-
stimulated release [42]. Thus despite low
expression levels, we can conclude that
functional inhibitory H3R are present in
dopaminergic neurons projecting to the
prefrontal cortex, dorsal striatum and Acb.
Colocalization of PE or SP mRNA
with H3R mRNA in the striatum and nucleus
accumbens (Fig. 3) confirms H3R expression
in all GABAergic medium spiny projection
neurons [43,44]. In striatonigral neurons,
H3R are functional taking into account that:
1) H3R stimulation reduces dopamine D1
receptor-dependent GABA release [11]; 2)
H3R stimulation inhibits dopamine D1
receptor-stimulated cAMP accumulation
[45], and 3) D1R - H3R receptor heteromers
stimulate MAP kinase specifically in these
cells [44]. In striatopallidal neurons, H3R
presence agrees with 1) a previous report of
H3R mRNA in PE positive neurons [46] and
2) colocalization of D2 and H3
immunolabelling [44]. However, proof of
H3R functionality in striatopallidal neurons
is still insufficient. D2 and H3 receptors can
interact forming heteromers in living cells in
vitro, and locomotor tests suggest they
could also interact in vivo [46,47], but it is
still uncertain whether this interaction
actually occurs in striatal neurons [48].
Recently, Ellender et al. (2011) [39]
reported that histamine modulates lateral
inhibition between collaterals of striatal
medium spiny neurons, although the
authors did not test H3R involvement in this
effect.
Currently, the existence of a
population of medium spiny neurons which
coexpress D1 and D2 receptors is accepted
[21,49]. In addition, all neurons expressing
D1 receptors appear to contain low levels of
D2 receptors and vice versa [20]. In the
ventral striatum a subset of D1 and D2
receptor-expressing neurons coexpress
dopamine D3 receptors [50]. Additional
populations of striatal efferent neurons
coexpress (1) D4 and D5 receptors [51], (2)
D1 receptors, SP and also PE, projecting to
the SNc [52], and (3) D1 receptors and
neurokinin B (but not SP or PE), projecting
to the substantia innominata [19]. Thus,
separation of neuronal populations can not
be performed based on D1 receptor
labelling. In this paper all H3R protein
immunoreactive neurons in the studied
areas showed D1 protein immunoreactivity
(Fig. 4). This might imply H3R expression in
neurons where D1 and D2 receptors are
colocalized, but we did not attempt to
demonstrate this by triple labelling. The
specificity of the dopamine D1 receptor
antibody used here was described by
Narushima et al. [53]. In Narushima's paper,
partial colocalization of D1 and D2 receptor
immunoreactivities was apparent in some
pictures. Further work should confirm
whether H3R are expressed in D1 - D2
positive cells.
GABAergic and cholinergic
interneuron arborizations in the
caudate/putamen would explain neuropil
colocalization between D1 receptors and
H3R (Fig. 4). In contrast, glutamatergic
inputs are described to express only the D2-
like class of dopamine receptors [54].
Similarly, the D1R - H3R protein
colocalization found in the medial
prefrontal cortex could be due to the H3R
presence in the D1R-expressing GABAergic
interneurons of the cortex.
It is well known that excitatory
corticostriatal afferents to the striatum
innervate both populations of medium-
sized spiny GABAergic projection neurons
[55]. We found H3R immunoreactivity in
corticostriatal glutamatergic inputs to the
striatum (Fig. 6). The colocalization of H3R
and VGLUT1 agrees with functional studies
showing that 1) the H3R inverse agonist
thioperamide at 100 nM changed the
paired-pulse ratio of corticostriatal
synapses (Fig. 7A), an index of altered
probability of presynaptic neurotransmitter
(glutamate) release [56]; 2) H3R mediate the
synaptic depression induced by histamine in
corticostriatal inputs [57,39]. Conversely,
the H3R inverse agonist thioperamide
relieves the repression exerted by
presynaptic H3R on glutamatergic terminals,
allowing an increased release of presynaptic
glutamate that potentiates field potentials
(Fig. 7B). The concentration of thioperamide
we used in the present study (100 nM)
should fully occupy H3R, although it is much
lower than that used in Doreulee and
Ellender studies (10 M) to block histamine-
induced synaptic depression. We must note
that bath application of 10 M
thioperamide alone did not affect field
potential amplitude or paired pulse ratios
(data confirmed by us, in agreement with
previous studies [57, 39]). We do not have
an explanation for thioperamide
concentration-dependent effects, but we
could speculate that higher concentrations
may have effects on an additional subset of
receptors (and see [13]). Independently of
that, Ellender et al. (2011) [39] suggested
that H3R mediate histamine depression of
corticostriatal synapses and favor
thalamostriatal transmission, but the
presence of H3R in thalamostriatal terminals
has not yet been demonstrated. H3R
activation in striatal synaptosomes inhibits
glutamate release [10], but striatal
synaptosomes may be formed from cortical,
thalamic or additional inputs. Taken
together, we can conclude that functionally
inhibitory H3R are present in corticostriatal
terminals, limiting glutamate release.
Our results show that striatal
cholinergic neurons present histamine H3
receptor immunoreactivity. Due to the low
number of striatal cholinergic interneurons,
we were unable to show direct effects of
H3R ligands specifically in these cells, but
there are numerous studies where H3R
modulation of acetylcholine release has
been observed in diverse brain regions: (1)
in the amygdala H3R agonists increased
acetylcholine release [58]; (2) in the cortex
H3R agonists decreased acetylcholine
release [32,33]; (3) in the hippocampus H3R
antagonists increased acetylcholine release
[59]; (4) in the ventral striatum of freely
moving rats acetylcholine release was
stimulated by both H3R agonists and inverse
agonists by acting at H3 receptors putatively
located in different populations of neurons,
although no evidence was obtained of
direct effects of H3 ligands on cholinergic
neurons [34]. Thus, the possibility that H3
receptors in striatal cholinergic
interneurons are functional is still uncertain.
Although we did not find H3R
presence in GFAP-immunoreactive
astrocytes in the medial prefrontal cortex,
striatum or nucleus accumbens, this
colocalization was recently shown at the
caudal spinal trigeminal nucleus of non-
human primates [60]. Thus H3R presence in
astrocytes could be limited to some areas.
In cultured astrocytes histamine seems to
act through H1 receptors to induce inositol
phosphate accumulation [61] and calcium
entry [62] but we have found no literature
evidence of H3 receptor-mediated effects in
astrocytes.
Due to the presence of functional
H3R in such different cellular types, what
role should these receptors have in striatal
function? Regarding locomotion, it has been
shown that histamine action on H3R elicits a
fast hypokinetic effect, and afterwards
histamine would activate H1 receptors to
elicit hyperactivity [23]. The hypokinetic
effect could be explained by a transient
decrease of dopamine neurotransmission
provoked by H3R stimulation. However H3R
KO mice exhibit lower locomotion than
wild-type mice [24], a finding that is hard to
reconcile with the H3-mediated hypokinetic
effect and with the observation that H3
antagonists do not change locomotor
activity. An interpretation given by these
authors is that the absence of H3 inhibitory
autoreceptors in histamine neurons of KO
mice could favor histamine release, which
could decrease neuronal histamine levels,
which in turn could decrease activation of
H1 receptors [24]. Developmental
adaptations in H3R KO mice are difficult to
interpret given the varied cellular types
expressing H3R in the basal ganglia.
Several H3R agonists decrease L-
dopa and apomorphine-induced turning
behavior in 6-hydroxydopamine lesioned
rats [26,63] as well as L-dopa-induced
chorea in MPTP-lesioned monkeys [28].
These effects could be due to H3R-mediated
decrease of GABA release in the SNr [64]
(but see [65]). In reserpinized mice, H3
receptor stimulation decreases locomotion
induced by dopaminergic agonists [47].
These effects should be independent of H3R
expression in dopaminergic neurons. In
brains from Parkinson disease patients a
strong H3R binding was found in the SNr
[66]. Thus, it is likely that H3R in the
GABAergic direct pathway could account for
the majority of the effects of H3R agonists in
models of Parkinson's disease. H3R and D1R
in these neurons have opposite effects
[11,44] and dopaminergic lesions may
sensitize them [66,45].
The effects of H3R antagonists /
inverse agonists in the basal ganglia can be
more difficult to interpret. H3R inverse
agonists would (1) stimulate histamine
release, which may lead to H1-mediated
effects such as hyperlocomotion [23,67]
and H2-mediated depolarization of medium
spiny neurons [39]; (2) facilitate glutamate
release from corticostriatal terminals (Fig.
7); and (3) stimulate cortical dopamine
release [40]. In reserpinized mice, the H3R
antagonists / inverse agonist thioperamide
potentiates locomotion elicited by
dopaminergic agonists [47]. However,
antagonism of H3R in striatonigral neurons
could also block D1-H3 receptor heteromers
[44], whose involvement in locomotion is
uncertain, but could contribute to
dopamine-mediated effects. D1-H3 receptor
heteromers work as processors integrating
dopaminergic and histaminergic signals that
can be blocked by antagonists of either
receptor protomer composing the
heteromer [44]. According to H3R
expression in several neuronal types of the
basal ganglia, further studies would be
needed to determine whether H3R ligands
could be therapeutically useful in
Parkinson's disease or related movement
disorders [68]. Similarly, further studies of
H3R antagonists / inverse agonists would be
advisable in models of other disorders
where the basal ganglia play a central role
such as attention-deficit hyperactivity
disorder, schizophrenia and alcohol abuse
[25,26]. The fact that each neuronal
pathway involved expresses H3R difficults
prediction of the predominant functional
effects of H3R antagonists / inverse
agonists. We expect these ligands would
favor histamine actions on other histamine
receptor subtypes, but their effects on
glutamatergic and dopaminergic
neurotransmissions must also be
considered.
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Table 1. List of antibodies (A) and fluorescent detection systems (B) used for
immunofluorescence and fluorescent in situ hybridization studies. Histamine H3 receptor
protein was detected using the Abcam 13014 antibody in dopaminergic and cholinergic
neurons and the Alpha Diagnostic H3R31A antibody in the rest of experiments.
A
Antigen Abbreviation Dilution Reference Host
Histamine H3 receptor anti-H3Rab 1/300 Abcam (ab-13014) Rabbit (P)
Histamine H3 receptor anti-H3Rc 1/200 Chemicon (ab5660) Rabbit (P)
Histamine H3 receptor anti-H3Ral 1/200 Alpha Diagnostic (H3R31-A) Rabbit (P)
Tyrosine Hydroxylase anti-TH 1/500 Millipore (AB1542) Sheep (P)
Dopamine D1 receptor anti-D1 1/300 Frontier Institute (D1rgpaf501) G. Pig (P)
Choline Acetyl Transferase anti-ChAT 1/100 Chemicon (ab144P) Goat (P)
Vesicular Glutamate Transporter 1 anti-VGLUT1 1/300 Synaptic Systems (135 511) Mouse (M)
Glial fibrillary Acidic Protein anti-GFAP 1/500 Sigma Aldrich (G3893) Mouse (M)
P, polyclonal; M, monoclonal
B
Detection system Dilution Source Host
Anti Digoxigenin -peroxidase 1/100 Roche (11207733910) Sheep
Anti-rabbit-peroxidase 1/200 Cell signalling (7074) Goat
Anti biotine 1/200 Jackson Immun. (200-002-211) Mouse
Anti mouse -Alexa 488 1/200 Invitrogen (A11029) Goat
Anti sheep -FITC  1/40 Sigma Aldrich (F7634) Donkey
Anti goat -Alexa 488 1/200 Invitrogen (A11055) Donkey
Anti guinea pig -Alexa 488 1/200 Invitrogen (A11073) Goat
Anti rabbit –Alexa594 1/200 Invitrogen (A21442) Chicken
TSA-Cy3 (amplification system) 1/100-500 Perkin Elmer (NEL 744) -
Hoechst 33258 1/10000 Invitrogen (H3569) -
Figure 1. H3R expression in mesencephalic dopamine neurons. A) Representative
colocalization of H3R and TH mRNAs (upper images) and protein immunoreactivities (lower
images) in the VTA (scale bar 40µm). B) Colocalization of H3R and TH mRNAs (upper images)
and protein immunoreactivities (lower images) in the SNc (scale bar, 40µm). Images are
representative of three brain sections obtained from different animals. H3R protein
immunoreactivity is detected with the Abcam rabbit anti-H3R antibody and an anti-rabbit
secondary coupled to DIG. H3R mRNA is detected with a H3R-specific cRNA-DIG probe. In both
protocols, an anti-DIG-peroxidase antibody is used followed by TSA-Cy3 signal amplification,
which gives a red labelling to H3R expressing cells. TH protein is detected with a sheep anti-TH
antibody and an anti-sheep FITC-coupled secondary antibody. TH mRNA is detected with a
cRNA-biotin probe, followed by a mouse anti-biotin antibody and an anti-mouse Alexa 488-
coupled antibody. In both cases a green label shows TH-expressing cells. Yellow arrows show
neurons with positive colocalization.
Figure 2. Inhibition of dopamine synthesis by a H3R agonist. The H3R agonist imetit dose-
dependently decreased 3H-dopamine synthesis in fresh striatal miniprisms incubated with 3H-
tyrosine. Data shown are obtained from individual incubations and expressed as % of
dopamine synthesis versus control samples. 100% dopamine synthesis in control samples was
162667 dpm. This result was representative of three independent experiments performed with
brains obtained from three different animals. Estimated IC50 was 20 nM. * p<0.01 vs controls,
one-way ANOVA and Dunnett post-hoc test.
Figure 3. H3R mRNA expression in GABAergic medium spiny projection neurons of the
striatum and nucleus accumbens. A) H3R mRNA colocalization with SP mRNA B) H3R mRNA
colocalization with PE mRNA. Images are representative of three brain sections obtained from
different animals. H3R mRNA is detected as a red fluorescent signal obtained using a H3R-
specific cRNA-DIG probe recognized by an anti-DIG-peroxidase antibody and followed by a TSA-
Cy3 signal amplification. PE or SP mRNAs are detected as green fluorescence signals obtained
using PE or SP cRNA-Biotin probes recognized by a mouse Anti-biotin antibody and followed by
a goat anti-mouse Alexa 488-coupled antibody. White arrows show neurons single-labelled
with H3R mRNA only. Yellow arrows show positive neurons for both probes. Scale bar 40µm.
Figure 4. Colocalization of H3R and D1R immunoreactivities. H3R and D1R protein
immunolabelling colocalize at neuronal bodies of the medial prefrontal cortex, dorsal striatum
and nucleus accumbens (overlap values 0.71±0.01, 0.67±0.05 and 0.71±0.03 respectively) and
neuropil of these areas (overlap values 0.70±0.02, 0.70±0.03 and 0.74±0.04 respectively. No
neurons were found with only H3R immunoreactivity. Images are representative of three brain
sections obtained from different animals. H3R protein is detected as red fluorescence obtained
with the Alpha Diagnostic rabbit anti-H3R antibody followed by an anti-rabbit-peroxidase and
the TSA-Cy3 system. D1 protein is detected as green fluorescence obtained with the guinea pig
anti-D1 antibody followed by the goat anti-guinea pig-Alexa488 antibody. Yellow arrows show
positive neurons for both antibodies. Asterisks mark colocalization of immunoreactivity at
nerve terminals. The insert show a zoom (7x) of the area marked by the asterisk. Scale bar
20µm.
Figure 5. Presence of H3R immunoreactivity in cholinergic (ChAT-immunoreactive) neurons in
striatum and nucleus accumbens. ChAT immunoreactivity is found in big size H3R-
immunoreactive neurons. H3R positive – ChAT negative neurons are also found. Images are
representative of three different brain sections obtained from three animals. H3R protein is
detected as red fluorescence obtained with the Abcam rabbit anti-H3R antibody developed
with a chicken anti-rabbit-Alexa594 antibody. ChAT protein is detected as green fluorescence
obtained by the goat anti-ChAT antibody developed with the donkey anti-goat-Alexa488
antibody. White arrows show neurons with H3R protein immunoreactivity only. Yellow arrows
show colocalization of both antibodies. Scale bar 40µm
Figure 6. Presence of glutamatergic (VGLUT1-immunoreactive) terminals surrounding H3R
immunoreactive neurons. There is a clear terminal-axon (neuropil) VGLUT1 pattern of
expression that spares most H3R labelling located in the cell bodies. Colocalization between
H3R and VGLUT1 can be found in the neuropil of the medial prefrontal cortex, striatum and
nucleus accumbens (overlap values 0.68±0.08, 0.75±0.08 and 0.72±0.04 respectively) and in
the external border of some H3R immunoreactive neurons (overlap values 0.54±0.03, 0.60±0.03
and 0.62±0.05 respectively in the same regions). Images are representative of three brain
sections obtained from different animals. H3R protein is detected as red fluorescence obtained
with the Alpha Diagnostic rabbit anti-H3R antibody followed by an anti-rabbit-peroxidase and
the TSA-Cy3 system. VGLUT1 protein is detected as green fluorescence by the mouse anti-
VGLUT1 antibody developed with the goat anti-mouse-Alexa488 antibody. Yellow arrows show
positive neurons for both antibodies while asterisks mark immunoreactive colocalization at
terminals. The insert shows a zoom (5x) of the neurons marked with a yellow arrow, where
VGLUT1 protein is detected in the external border of H3R immunoreactive neurons. Bar 20µm.
Figure 7. Effect of the H3R inverse agonist thioperamide on excitatory cortico-striatal
synaptic transmission. A) Long-lasting enhancement of synaptic transmission and B) decrease
in paired-pulse facilitation ratio induced by thioperamide. Excitatory field potentials (fEPSP)
were evoked by either single (A) or paired (B) stimuli of cortico-striatal afferents. As shown in
A, thioperamide (100nM, 30min) induced a slow-onset increase in fEPSP amplitude which
continued up to 20min after washout. On the graph, data are means ± SEM (n = 3-5 slices
obtained from different animals) of fEPSP amplitudes normalized to their respective baseline
activity. In B, pooled paired-pulse facilitation ratio measured 5 min before and 20 min after
thioperamide washout are shown. Paired-pulse facilitation was obtained by delivering two
stimuli with a 50ms interval. Paired-pulse facilitation ratio was further calculated by dividing
the second peak amplitude (P2) by the first one (P1). On the graph, data are expressed as
averages of paired-pulse ratios (P2/P1) ± SEM obtained from 5 individual experiments where
each determination is the mean of 8 consecutive fEPSP. The decrease of the paired-pulse ratio
suggests that presynaptic H3R alter the probability of neurotransmitter release. Representative
electrophysiological traces are shown above each graph. They were extracted during baseline
activity and 20min after thioperamide washout when signals reached a stable amplitude. In
both A and B changes were statistically significant (* p<0.05 versus controls, repeated
measures ANOVA).
Figure 8. Absence of H3R protein expression in astrocytes (GFAP-immunoreactive cells) in the
rat forebrain. GFAP-positive astrocytes surround H3R immunolabelled neurons in the medial
prefrontal cortex, striatum and nucleus accumbens. Overlap values obtained were always
lower than 0.5, the preestablished threshold to detect colocalization. Images are
representative of three brain sections obtained from different animals. H3R protein is detected
as red fluorescence obtained with the Alpha Diagnostic rabbit anti-H3R antibody followed by an
anti-rabbit-peroxidase and the TSA-Cy3 system. GFAP protein is detected as green fluorescence
obtained with the mouse anti-GFAP antibody developed with the goat anti-mouse-Alexa488
antibody. White arrows show immunostained cells for only one of the antigens. Scale bar
20µm.
Figure S1. Comparison between sense and antisense H3R cRNA probes. A faint signal due to
low non-specific binding of the sense H3R cRNA probe can be found in the VTA, but it is almost
undetectable when compared with the specific signal. Scale bar 35µm.
Figure S2. Comparison among diverse H3R commercial antibodies. Similar H3R
immunostaining pattern was obtained by using three different commercial antibodies. Alpha
Diagnostic anti-H3R (anti-H3Ral) signal was completely abolished by preincubation with its
blocking peptide. See Table 1 for antibody details. Scale bar 35µm.
